The success of this treatment against tumors is suggesting that it might be extended to defend more common cancers shortly. The procedure is known as CAR-T therapy. It makes genetic changes to a few of the patient's own cells to make them acknowledge it and attack cancer.

Richard Carlstrand from Long Key, Florida had the CAR-T therapy over a year ago for pleural mesothelioma, cancer that grows in the lining of the lungs. To The Associated Press, he told that some unknown territories were tried for the treatment. Now Carlstrand said happily that nothing could be happier than his having no sign of cancer.

Last month experts have discussed various case results at a conference of American Association for Cancer Research held in Atlanta, Georgia.

In 2017, the first 2 CAR-T therapies for leukemia and lymphoma got approval from the United States Food and Drug Administration. Leukemia affects a person's blood and bone marrow. Lymphoma starts at infection-fighting cells of the immune system of the body.

Researchers start the treatment by reversing immune system cells inside a laboratory. After the alteration, they inject back the cells to the affected patient through the intravenous drip. This method puts the cells at the place of cancer in the blood.

But if the cells have to traverse far via the bloodstream, then the method works not so well to get to the affected areas in the breast, lungs and other places.

Prasad Adulsumilli, the doctor of the Memorial Sloan Kettering Cancer Center in New York City, notes that in such cases enough cells couldn't make it to cancer affected area. Solid cells forbid immune cells to enter the area.